Immune targeted therapy for diffuse large B cell lymphoma

Abstract. Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, is highly heterogeneous and invasive. Although the majority of DLBCL patients show a good response to rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone treatment, approximately o...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Yaxin Zheng, Junqi Si, Tian Yuan, Sa Ding, Chen Tian
Formato:	article
Lenguaje:	EN
Publicado:	Wolters Kluwer Health 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/75a8f873e7dc4771afaed696df2c52a6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:75a8f873e7dc4771afaed696df2c52a6
record_format	dspace
spelling	oai:doaj.org-article:75a8f873e7dc4771afaed696df2c52a62021-11-25T07:49:34ZImmune targeted therapy for diffuse large B cell lymphoma2543-636810.1097/BS9.0000000000000095https://doaj.org/article/75a8f873e7dc4771afaed696df2c52a62021-10-01T00:00:00Zhttp://journals.lww.com/10.1097/BS9.0000000000000095https://doaj.org/toc/2543-6368Abstract. Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, is highly heterogeneous and invasive. Although the majority of DLBCL patients show a good response to rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone treatment, approximately one-third of patients still have a poor prognosis. Many immune-targeted drugs, such as bispecific T-cell engagers and CAR T-cell therapy, have been proven effective for refractory and relapsed patients. This article reviews the progress of immune targeted therapy for DLBCL.Yaxin ZhengJunqi SiTian YuanSa DingChen TianWolters Kluwer HealtharticleDiseases of the blood and blood-forming organsRC633-647.5ENBlood Science, Vol 3, Iss 4, Pp 136-148 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Yaxin Zheng Junqi Si Tian Yuan Sa Ding Chen Tian Immune targeted therapy for diffuse large B cell lymphoma
description	Abstract. Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, is highly heterogeneous and invasive. Although the majority of DLBCL patients show a good response to rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone treatment, approximately one-third of patients still have a poor prognosis. Many immune-targeted drugs, such as bispecific T-cell engagers and CAR T-cell therapy, have been proven effective for refractory and relapsed patients. This article reviews the progress of immune targeted therapy for DLBCL.
format	article
author	Yaxin Zheng Junqi Si Tian Yuan Sa Ding Chen Tian
author_facet	Yaxin Zheng Junqi Si Tian Yuan Sa Ding Chen Tian
author_sort	Yaxin Zheng
title	Immune targeted therapy for diffuse large B cell lymphoma
title_short	Immune targeted therapy for diffuse large B cell lymphoma
title_full	Immune targeted therapy for diffuse large B cell lymphoma
title_fullStr	Immune targeted therapy for diffuse large B cell lymphoma
title_full_unstemmed	Immune targeted therapy for diffuse large B cell lymphoma
title_sort	immune targeted therapy for diffuse large b cell lymphoma
publisher	Wolters Kluwer Health
publishDate	2021
url	https://doaj.org/article/75a8f873e7dc4771afaed696df2c52a6
work_keys_str_mv	AT yaxinzheng immunetargetedtherapyfordiffuselargebcelllymphoma AT junqisi immunetargetedtherapyfordiffuselargebcelllymphoma AT tianyuan immunetargetedtherapyfordiffuselargebcelllymphoma AT sading immunetargetedtherapyfordiffuselargebcelllymphoma AT chentian immunetargetedtherapyfordiffuselargebcelllymphoma
_version_	1718413626301218816

Immune targeted therapy for diffuse large B cell lymphoma

Ejemplares similares